Patent TW-515796-B (TW)
Title: Therapeutic benzamide derivatves
Inventor: DAUGAN ALAIN CLAUDE-MARIE
IPC: C07D295/12
Filed: 1999-12-06
Granted: 2003-01-01
Abstract: The invention relates to therapeutic benzamide compounds of formula (I), wherein A represents N or CH; X is selected from the following groups: (i) -C1-6alkylene-, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, C1-6alkyl, C1-6alkoxy, C1-6acyl or C1-6acyloxy groups, (ii) oxo, sulfonyl, thioxo, (iii) -C1-6alkylenecarbonyl-, -C1-6alkylenesulfonyl-, -C1-6alkylenethioxo-, (iv) -C2-6alkyleneoxy-, -C2-6alkylenethio-, -C2-6alkylene(N-H or N-C1-6alkyl)amino-, (v) -C1-6alkylenecarboxy-, -C1-6alkylenethioamido-, -C1-6alkylene(N-H or N-C1-6alkyl)carboxamido-, and (vi) -C2-6alkyleneoxycarbonyl-, -C2-6alkylenethiocarbonyl-, -C2-6alkylene(N-H or N-C1-6alkyl)aminocarbonyl-; Z represents a direct link or -C1-6alkylene-, optionally containing one double bond and optionally substituted by one or more hydroxy, C1-6alkyl, C1-6alkoxy, C1-6acyl or C1-6acyloxy groups; R1 is selected from the following groups: (i) hydrogen, C1-3perfluoroalkyl, (ii) C6-10aryl, C3-8cycloalkyl and fused benz derivatives thereof, C7-10polycycloalkyl, C4-8cycloalkenyl, C7-10polycycloalkenyl, (iii) a heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-14 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, and (iv) where either X is C1-6alkylene and Z is a direct link, or Z is C1-6alkylene, R1 additionally may represent a halogen, cyano, nitro or C1-6acyl group, wherein, when R1 contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from (i) halogen, hydroxy, cyano, nitro, formyl, C1-6alkylsulfonylamino, (ii) C1-6alkyl, C3-8cycloalkyl, C1-3perfuoroalkyl, (iii) C1-6alkoxy, methylenedioxy, C1-3perfuoroalkoxy, C1-6alkylthio, (iv) amino, C1-6alkylamino, di-C1-6alkylamino, (v) phenyl, phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy, (vi) hydroxycarbonyl, C1-6alkoxycarbonyl, (vii) aminocarbonyl, C1-6alkylaminocarbonyl, di-C1-6alkylaminocarbonyl, di-C1-6alkylaminocarbonyl-C1-6alkoxy, C1-3perfluoroalkylaminocarbonyl, (viii) C1-6acyl, C1-6acyloxy, C1-6acyloxyc1-6alkyl, C1-6acylamino, and (ix) an aromatic heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and where each of the said heterocyclyl groups is optionally substituted by one or more groups independently selected from halogen, C1-4alkyl, C1-4alkoxy, C1-3perfuoroalkyl and C1-3perfuoroalkoxy; Y represents a direct or oxy link, -C1-6alkylene-, -oxyC1-6alkylene- or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5 ring atoms, and wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur and wherein the ring may be independently saturated, partially unsaturated, or aromatic; R2 represents phenyl, C3-8cycloalkyl, or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain a total of from 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, wherein the ring may be independently saturated, partially unsaturated, or aromatic, and where each R2 is optionally substituted by one or more groups independently selected from halogen, C1-4alkyl, C1-4alkoxy, C3-8cycloalkyl, C1-3perfuoroalkyl, C1-3perfuoroalkoxy, hydroxycarbonyl, C1-6alkoxycarbonyl, cyano, nitro, C1-4alkylaminosulfonyl; R3 represents hydrogen or one or more groups independently selected from halogen, C1-4alkyl, C1-4alkoxy, C1-3perfluoroalkyl or C1-3perfluoroalkoxy; or a physiologically acceptable salt, solvate or derivative thereof, pharmaceutical compositions, to processes for their preparation and their use in the treatment of conditions mediated by ApoB-100 regulation.